Loading...
•
Sep 30, 2023
Ultragenyx Q3 2023 Earnings Report
Reported third quarter results with total revenue of $98.1 million, Crysvita® revenue of $74.9 million, and Dojolvi® revenue of $16.6 million, while reaffirming 2023 revenue guidance.
Key Takeaways
Ultragenyx reported $98.1 million in total revenue for the third quarter 2023, representing 8% growth compared to the third quarter 2022. The company reaffirmed its 2023 expected total revenue guidance between $425 million to $450 million.
Total revenue for Q3 2023 was $98.1 million, an 8% increase compared to Q3 2022.
Crysvita revenue for Q3 2023 was $74.9 million.
Dojolvi revenue for Q3 2023 was $16.6 million.
The company reaffirmed its 2023 total revenue guidance of $425 million to $450 million.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
For the full year 2023, the company expects total revenue in the range of $425 million to $450 million, Crysvita revenue in the range of $325 million to $340 million, and Dojolvi revenue in the range of $65 million to $75 million. Net Cash Used in Operations to be around $425 million
Positive Outlook
- Total revenue in the range of $425 million to $450 million
- Crysvita revenue in the range of $325 million to $340 million
- Dojolvi revenue in the range of $65 million to $75 million
Challenges Ahead
- Net Cash Used in Operations to be around $425 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...